Management of Hypomagnesemia in Patients on Osimertinib

Osimertinib-Specific Considerations

• The National Comprehensive Cancer Network recommends continuing osimertinib at full dose (80 mg daily) while treating hypomagnesemia, as this electrolyte abnormality alone does not warrant dose modification or treatment interruption 3
• EGFR-targeted therapies, including osimertinib, can cause electrolyte disturbances, and patients require routine metabolic monitoring throughout treatment 1

Critical Monitoring Requirements

• The American Heart Association and other guideline societies imply that osimertinib is contraindicated in patients with mean resting QTc >470 msec, and hypomagnesemia exacerbates QTc prolongation and increases risk of torsades de pointes 1
• Correct magnesium deficiency before continuing osimertinib if QTc is borderline elevated, according to guidelines from medical societies 1

Common Pitfalls to Avoid

• Do not discontinue osimertinib for isolated hypomagnesemia, as this level does not meet criteria for treatment interruption, based on recommendations from the National Comprehensive Cancer Network and other medical societies 2
• Osimertinib should only be held for severe concurrent cytopenias or life-threatening toxicities like pneumonitis, as stated by medical guideline societies 1, 2